Therapeutic antibody developer Patrys (ASX: PAB) has said it has completed its pilot study into its drug candidate PAT-DX1, one of six different assets it has in development and currently at the pre-clinical stage.
The pilot study showed that PAT‐DX1 has “antitumor activity” in an orthotopic, immune‐competent mouse model of triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer.
Patrys is also working on similar applications of this technology towards the treatment of brain cancers known as glioblastomas.
Detailed research findings will be published in due course with Patrys saying it will make an official statement upon their publication.
Immediately after completing the study, the company said it is initiating a research and development collaboration bringing together experts from Yale School of Medicine in New Haven, Connecticut and Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts.
The expanded research program will be led by Dr James Hansen of Yale and Drs Gerburg Wulf and Jaymin Patel from the Israel Deaconess Medical Center, to further investigate PAT‐DX1.
Dr Hansen is an expert in cell‐penetrating antibodies and is the inventor of the novel Deoxymab technology which Patrys intends to run through clinical trials and ultimately commercialise in the treatment of various cancers.
“The opportunity to build on the successful pilot study and to further investigate PAT‐DX1 in an immunocompetent mouse model of TNBC is timely, following the successful completion of the PAT‐DX1 orthotopic glioblastoma study completed at Yale University in March,” said Dr James Campbell, CEO and managing director of Patrys.
“Patrys’ novel position in the field of DNA damage repair antibody therapeutics is increasingly being recognized, resulting in collaborations such as this one between the company, Yale University and the Beth Israel Deaconess Medical Center”, added Dr Campbell.